calcipotriol
Small moleculeexperimental
Calcipotriol, also known as calcipotriene and sold under the brand name Dovonex among others, is a synthetic derivative of calcitriol, a form of vitamin D. It is used in the treatment of psoriasis. — Wikipedia
Clinical trial activity
36 trials · 21 clinical orgs · 0 marketing orgs
Phase 1
10
Phase 2
25
Phase 3
10
Phase 4
0
Earliest trial started Apr 1, 2008 (NCT00670241)
Timeline
Indications
Mechanism of action
- Vitamin D receptorAGONIST
VDR agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCalcipotriol ↗
Also known as
- leo 19123
- leo 80185
- leo 80185
- leo 80190
- leo90100
- leo 90100
- leo 90105
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06011083 | N/A | Aug 1, 2022 | Assiut University |
| NCT05249972 | Phase 3 | Jan 24, 2022 | Lipidor AB |
| NCT04642287 | Phase 2 | Jul 31, 2021 | Harvard University, Washington University in St. Louis |
| NCT04329221 | Phase 2 | Jun 30, 2020 | Harvard University, Washington University in St. Louis |
| NCT04440371 | N/A | Jun 30, 2020 | Jordan University |
| NCT05174598 | Phase 3 | Oct 3, 2018 | Cadila Healthcare |
| NCT03476746 | Phase 1 | Mar 20, 2018 | Leo Pharma |
| NCT03442244 | Phase 1 | Jan 30, 2018 | Leo Pharma |
| NCT02899962 | Phase 3 | Feb 15, 2017 | Icahn School of Medicine at Mount Sinai, Leo Pharma |
| NCT02973776 | Phase 1 | Dec 1, 2016 | Leo Pharma |
| NCT02387853 | Phase 2 | Mar 1, 2016 | Leo Pharma, Radboud University |
| NCT02668692 | Phase 3 | Feb 1, 2016 | CMIC Co, Ltd. Japan, Jikei University, Leo Pharma |
| NCT02605057 | Phase 1 | Nov 1, 2015 | Leo Pharma |
| NCT02518048 | Phase 2 | Aug 1, 2015 | Leo Pharma |
| NCT02416258 | Phase 2 | Apr 1, 2015 | Leo Pharma |
| NCT02379793 | Phase 1 | Mar 1, 2015 | Leo Pharma |
| NCT02310646 | Phase 3 | Jan 1, 2015 | K. Papp Clinical Research, Leo Pharma |
| NCT02132936 | Phase 3 | Jun 1, 2014 | Leo Pharma |
| NCT02038569 | Phase 2 | Jan 1, 2014 | Leo Pharma, University of California, San Diego |
| NCT01946386 | Phase 1 | Sep 1, 2013 | Leo Pharma |
Showing 20 of 36 trials
Page 1 / 2
Organizations
Research & Development (21)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Leo Pharma | For profit | 30 | 30 | 3 | 2008 |
| IQVIA | For profit | 3 | 0 | 2 | 2010 |
| Hakata Clinic Medical Co. LTA | For profit | 2 | 0 | 1 | 2010 |
| Harvard University | Academic/Hospital | 2 | 2 | 1 | 2020 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 2 | 0 | 2 | 2012 |
| University of California, San Diego | Academic/Hospital | 2 | 0 | 1 | 2010 |
| Washington University in St. Louis | Academic/Hospital | 2 | 0 | 1 | 2020 |
| Assiut University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Cadila Healthcare | For profit | 1 | 1 | 1 | 2018 |
| CMIC Co, Ltd. Japan | For profit | 1 | 0 | 1 | 2016 |
| Eastern Canada Cutaneous Research Associates Ltd. | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Jikei University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Jordan University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| K. Papp Clinical Research | For profit | 1 | 0 | 1 | 2015 |
| Lipidor AB | For profit | 1 | 1 | 1 | 2022 |
| Radboud University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Royal Gwent Hospital | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Tokai University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| UltraNova Skincare | For profit | 1 | 0 | 1 | 2008 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2012 |
21 organizations
Page 1 / 2